Galera Therapeutics, Inc.

GRTXOTCHealthcare● Active

$0.09

+$0.01(+8.24%)

Market Cap$6982143

P/E Ratio—

52W High$0.15

52W Low$0.015

Avg Volume298K

Open$0.09

Beta2.59

Overview

Galera Therapeutics, Inc. (GRTX) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · GRTX · as of Jun 15, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

21.00

Buy/Sell (by trades)

Overall sentiment

BULLISH

↑ Buy 95%Active transactions only · RSU vesting excluded5% Sell ↓

Galera Therapeutics, Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 15, 2026

GRTX insider buying and selling by quarter

GRTX insider selling · GRTX insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

7.7M3.8M0

2023 Q2

2023 Q3

2023 Q4

2024 Q1

2024 Q2

2024 Q3

2024 Q4

2025 Q1

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 15, 2026

Active insiders

Most active in past 12 months · GRTX ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

GRTX executive sell shares · GRTX board member insider trading · GRTX insider trading SEC filing

Showing 20 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
May 15, 2026	Emerald Bioventures, LLC 10 percent owner	Other	20,813,818	—	—	61,029,978	Form 4
Apr 7, 2026	FRIEDMAN MICHAEL R. Director	Other	5,336,870	—	—	5,336,870	Form 4
Apr 7, 2026	CHANG NANCY T Director	Other	1,180,611	—	—	8,825,543	Form 4
Nov 20, 2025	Sorensen Mel President and CEO · Director	Sale	70,000	$0.02	$1K	195,029	Form 4
Dec 30, 2024	CHANG NANCY T Director	Purchase	7,644,932	$0.07	$500K	7,644,932	Form 4
Aug 16, 2024	Sorensen Mel President and CEO · Director	Sale	67,015	$0.07	$5K	265,029	Form 4
Feb 8, 2024	Schneid Yair 10 percent owner	Purchase	150,000	$0.17	$26K	8,043,203	Form 4
Feb 7, 2024	Schneid Yair 10 percent owner	Purchase	150,000	$0.17	$26K	7,893,203	Form 4
Feb 7, 2024	Schneid Yair 10 percent owner	Purchase	25,000	$0.17	$4K	7,743,203	Form 4
Feb 6, 2024	Schneid Yair 10 percent owner	Purchase	25,000	$0.20	$5K	7,718,203	Form 4
Feb 5, 2024	Schneid Yair 10 percent owner	Purchase	97,402	$0.18	$18K	7,693,203	Form 4
Jan 30, 2024	Schneid Yair 10 percent owner	Purchase	335,000	$0.18	$61K	7,595,801	Form 4
Jan 29, 2024	Schneid Yair 10 percent owner	Purchase	150,000	$0.18	$27K	7,260,801	Form 4
Mar 16, 2023	Bachleda Mark Chief Commercial Officer	Purchase	11,000	$2.25	$25K	11,000	Form 4
Mar 10, 2023	Sorensen Mel President and CEO · Director	Purchase	100,000	$1.68	$168K	332,044	Form 4
Mar 13, 2023	Degnan Chris CFO	Purchase	10,000	$1.96	$20K	10,000	Form 4
Nov 21, 2022	Beardsley Robert A COO	Option	10,000	$1.07	$11K	108,191	Form 4
Jul 18, 2022	Alleva Lawrence M Director	Gift	4,000	—	—	2,325	Form 4
Dec 17, 2021	West Linda Director	Purchase	20,000	$2.74	$55K	60,000	Form 4
Dec 17, 2021	Beardsley Robert A COO	Option	20,000	$1.07	$21K	88,191	Form 4

Emerald Bioventures, LLC

10 percent owner

Other

Date

May 15

20,813,818

Price

—

Value

—

View Form 4 on SEC.gov

FRIEDMAN MICHAEL R.

Director

Other

Date

Apr 7

5,336,870

Price

—

Value

—

View Form 4 on SEC.gov

CHANG NANCY T

Director

Other

Date

Apr 7

1,180,611

Price

—

Value

—

View Form 4 on SEC.gov

Sorensen Mel

President and CEO · Director

Sale

Date

Nov 20

70,000

Price

$0.02

Value

$1K

View Form 4 on SEC.gov

CHANG NANCY T

Director

Purchase

Date

Dec 30

7,644,932

Price

$0.07

Value

$500K

View Form 4 on SEC.gov

Sorensen Mel

President and CEO · Director

Sale

Date

Aug 16

67,015

Price

$0.07

Value

$5K

View Form 4 on SEC.gov

Schneid Yair

10 percent owner

Purchase

Date

Feb 8

150,000

Price

$0.17

Value

$26K

View Form 4 on SEC.gov

Schneid Yair

10 percent owner

Purchase

Date

Feb 7

150,000

Price

$0.17

Value

$26K

View Form 4 on SEC.gov

Schneid Yair

10 percent owner

Purchase

Date

Feb 7

25,000

Price

$0.17

Value

$4K

View Form 4 on SEC.gov

Schneid Yair

10 percent owner

Purchase

Date

Feb 6

25,000

Price

$0.20

Value

$5K

View Form 4 on SEC.gov

Schneid Yair

10 percent owner

Purchase

Date

Feb 5

97,402

Price

$0.18

Value

$18K

View Form 4 on SEC.gov

Schneid Yair

10 percent owner

Purchase

Date

Jan 30

335,000

Price

$0.18

Value

$61K

View Form 4 on SEC.gov

Schneid Yair

10 percent owner

Purchase

Date

Jan 29

150,000

Price

$0.18

Value

$27K

View Form 4 on SEC.gov

Bachleda Mark

Chief Commercial Officer

Purchase

Date

Mar 16

11,000

Price

$2.25

Value

$25K

View Form 4 on SEC.gov

Sorensen Mel

President and CEO · Director

Purchase

Date

Mar 10

100,000

Price

$1.68

Value

$168K

View Form 4 on SEC.gov

Degnan Chris

CFO

Purchase

Date

Mar 13

10,000

Price

$1.96

Value

$20K

View Form 4 on SEC.gov

Beardsley Robert A

COO

Option

Date

Nov 21

10,000

Price

$1.07

Value

$11K

View Form 4 on SEC.gov

Alleva Lawrence M

Director

Gift

Date

Jul 18

4,000

Price

—

Value

—

View Form 4 on SEC.gov

West Linda

Director

Purchase

Date

Dec 17

20,000

Price

$2.74

Value

$55K

View Form 4 on SEC.gov

Beardsley Robert A

COO

Option

Date

Dec 17

20,000

Price

$1.07

Value

$21K

View Form 4 on SEC.gov

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About GRTX insider trading

GRTX insider trades

Galera Therapeutics, Inc. (GRTX) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Emerald Bioventures, LLC (10 percent owner), FRIEDMAN MICHAEL R. (Director), CHANG NANCY T (Director). Over the past 12 months, 4 insiders have filed transactions with the SEC. GRTX insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Galera Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

GRTX insider trading · 5 questions

The insiders of Galera Therapeutics, Inc. (GRTX) include executives and directors such as Emerald Bioventures, LLC (10 percent owner), FRIEDMAN MICHAEL R. (Director), CHANG NANCY T (Director), among others. Over the past 12 months, 4 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

GRTX board member insider tradingwho are GRTX insidersGRTX insider rosterGalera Therapeutics, Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 15, 2026